KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBT (2016 - 2025)

Historic EBT for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to -$37.6 million.

  • Pacific Biosciences Of California's EBT rose 3805.35% to -$37.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$503.2 million, marking a year-over-year decrease of 2740.65%. This contributed to the annual value of -$309.5 million for FY2024, which is 271.06% up from last year.
  • Pacific Biosciences Of California's EBT amounted to -$37.6 million in Q3 2025, which was up 3805.35% from -$41.9 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year EBT high stood at $2.7 million for Q4 2024, and its period low was -$426.4 million during Q1 2025.
  • Moreover, its 5-year median value for EBT was -$77.0 million (2022), whereas its average is -$87.9 million.
  • In the last 5 years, Pacific Biosciences Of California's EBT soared by 10324.77% in 2024 and then plummeted by 44539.26% in 2025.
  • Pacific Biosciences Of California's EBT (Quarter) stood at -$68.2 million in 2021, then decreased by 23.81% to -$84.4 million in 2022, then grew by 1.95% to -$82.7 million in 2023, then soared by 103.25% to $2.7 million in 2024, then plummeted by 1499.96% to -$37.6 million in 2025.
  • Its last three reported values are -$37.6 million in Q3 2025, -$41.9 million for Q2 2025, and -$426.4 million during Q1 2025.